HOME >> MEDICINE >> NEWS
GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix

PHILADELPHIA, PA, March 15, 2005 GlaxoSmithKline (NYSE: GSK) today announced that its booster vaccine candidate, BoostrixTM [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap)] received a unanimous favorable recommendation from the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration (FDA). Currently, there is no pertussis vaccine approved for use in the U.S. for children seven years of age or older. Immunity from childhood vaccination generally wears off after five to 10 years, leaving many adolescents susceptible to this highly contagious disease. If approved, Boostrix would add a pertussis component to the routine tetanus/diphtheria booster currently recommended for adolescents. The committee's favorable recommendation, although not binding, will be considered by the FDA in its final review of the Biologics License Application (BLA) for Boostrix.

Reported cases of pertussis have increased since the mid-1970s. According to the Centers for Disease Control and Prevention (CDC), there were almost 20,000 cases in 2004 the highest number of reported cases in more than 40 years. In addition, 39 percent of cases reported to the CDC in 2003 occurred in adolescents 10-19 years of age. Adolescents, in whom classic signs and symptoms of pertussis are often absent, may go undiagnosed and be the source of infection for susceptible infants and other family members.

"Pertussis is a serious and growing public health threat, and we are extremely pleased that the FDA Advisory Committee has provided a unanimous favorable recommendation for FDA approval of Boostrix," said Barbara Howe, M.D., vice president, Clinical Research and Development and Medical Affairs, Vaccines North America, GlaxoSmithKline. "If approved, Boostrix would add a pertussis component to the routine tetanus/diphtheria booster currently administered to adolescents a population in which there is a si
'"/>

Contact: Amanda Foley
919-483-2839
Cohn & Wolfe
15-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. TB Alliance announces new drug discovery program with GlaxoSmithKline
2. Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
3. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
4. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
5. GlaxoSmithKline Drug Discovery and Development Award 2002
6. GlaxoSmithKline Drug Discovery and Development Award 2002
7. UIC professor receives international humanitarian award
8. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
9. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
10. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
11. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2020)... ... September 02, 2020 , ... ... healthcare payers administering Medicare Advantage and Special Needs plans, is proud to support ... Health Insurance Plans (AHIP). RAM is supporting the event as a sponsor and ...
(Date:9/1/2020)... ... 2020 , ... Dr. Kiran Gill is a Board Certified ... face, breast, and body. In 2018, she founded Aesthetics in Plastic Surgery by ... practice in Southwest Florida. Dr. Gill and her team offer surgical and non-surgical ...
(Date:8/31/2020)... ... ... Want to get moving, break up your routine, and make a difference right ... its fourth annual STEPtember campaign in the United States to raise funds and awareness ... at this moment — encouraging people to move in the ways that work for ...
(Date:8/31/2020)... ... ... Covid-19 “PTS” with Mediation & Hypnosis , At this very turbulent time in the ... anxiety, immense stress, and right now are needing serious relief from a constant state of ... are experiencing a great degree of emotional discomfort, be it fear or worrying about their ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & ... was named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in ... whose ambitions deliver innovation, growth and prosperity as they build and sustain successful ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... ... Eurofins BioPharma Services, Laboratory Testing division, expands its technology footprint with the ... Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding ...
(Date:8/26/2020)... Va. (PRWEB) , ... August ... ... (CEA) Holdings company today announced that it has entered into definitive agreement ... professionals CME/CE, primarily focused on pharmacists and pharmacy technicians. , CEA ...
(Date:8/26/2020)... (PRWEB) , ... August 26, 2020 , ... ... RN, CHPN, CHPCA, LNC has added CHC and CPCO to her name. , ... Certification in Healthcare Compliance (CHC) and the Certified Professional Compliance Officer (CPCO.) , ...
Breaking Medicine Technology:
Cached News: